Want to see IN:FDC full AI Analyst Report?
Top Page
FDC Ltd.
(FDC)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹366.00
▼(-11.01% Downside)
Action:Reiterated
Date:08/28/26
The score is driven primarily by strong financial stability (especially the low-leverage balance sheet and steady revenue growth), partially offset by weak technicals showing a clear downtrend and bearish momentum. Valuation is supportive but not a major catalyst, with a reasonable P/E and modest dividend yield.
Positive Factors
Low Financial Leverage
A very conservatively financed balance sheet limits refinancing risk and preserves flexibility for operations, investment, and potential growth initiatives. Growing equity and assets also indicate a strengthening capital base over time.
Negative Factors
Volatile Free Cash Flow
Uneven free-cash-flow conversion reduces visibility into internally generated funding and may reflect working-capital swings or inconsistent investment timing. This can constrain the reliability of cash available for expansion, debt reduction, or distributions.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
A very conservatively financed balance sheet limits refinancing risk and preserves flexibility for operations, investment, and potential growth initiatives. Growing equity and assets also indicate a strengthening capital base over time.
Read all positive factors
FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹56.74B
Dividend Yield1.44%
Average Volume (3M)16.03K
Price to Earnings (P/E)19.1
Beta (1Y)0.70
Revenue Growth3.40%
EPS Growth8.71%
CountryIN
Employees6,916
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)17.98
Shares Outstanding162,810,090
10 Day Avg. Volume4,978
30 Day Avg. Volume16,030
Financial Highlights & Ratios
PEG Ratio3.51
Price to Book (P/B)2.10
Price to Sales (P/S)2.41
P/FCF Ratio83.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FDC Ltd. Business Overview & Revenue Model
Company Description
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infec...
FDC Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.90B | 21.71B | 21.08B | 19.35B | 17.84B | 15.26B |
| Gross Profit | 10.66B | 9.18B | 8.36B | 6.51B | 11.28B | 9.78B |
| EBITDA | 3.69B | 4.39B | 4.15B | 4.40B | 3.01B | 3.30B |
| Net Income | 2.93B | 2.81B | 2.67B | 3.05B | 1.94B | 2.16B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 29.19B | 27.14B | 24.68B | 23.43B | 22.70B |
| Cash, Cash Equivalents and Short-Term Investments | 5.23B | 5.23B | 5.37B | 4.75B | 4.84B | 5.39B |
| Total Debt | 0.00 | 154.65M | 211.68M | 205.19M | 283.20M | 322.04M |
| Total Liabilities | -24.85B | 4.34B | 4.33B | 3.71B | 3.62B | 3.14B |
| Stockholders Equity | 24.85B | 24.85B | 22.81B | 20.97B | 19.82B | 19.57B |
Cash Flow | ||||||
| Free Cash Flow | -833.81M | 622.92M | 2.67B | 1.27B | 418.21M | 291.08M |
| Operating Cash Flow | -19.40M | 2.49B | 3.64B | 2.21B | 1.55B | 1.62B |
| Investing Cash Flow | -68.14M | -1.59B | -2.47B | -170.83M | 111.35M | -1.45B |
| Financing Cash Flow | -70.98M | -925.39M | -913.47M | -2.02B | -1.80B | -98.37M |
FDC Ltd. Technical Analysis
Negative
411.30
Price Trends
395.38
Negative
383.92
Negative
384.35
Negative
Market Momentum
-15.27
Positive
29.87
Positive
24.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Negative. The current price of 411.3 is above the 20-day moving average (MA) of 363.13, above the 50-day MA of 395.38, and above the 200-day MA of 384.35, indicating a bearish trend. The MACD of -15.27 indicates Positive momentum. The RSI at 29.87 is Positive, neither overbought nor oversold. The STOCH value of 24.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FDC.
FDC Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹60.64B | 43.83 | ― | 0.28% | 20.59% | 27.16% | |
63 Neutral | ₹56.74B | 19.12 | ― | 1.21% | 3.40% | 8.71% | |
61 Neutral | ₹90.61B | 14.77 | ― | 0.39% | 7.28% | 68.82% | |
61 Neutral | ₹49.29B | 543.16 | ― | ― | 10.83% | -89.82% | |
57 Neutral | ₹37.37B | 12.47 | ― | ― | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | ₹22.05B | 836.31 | ― | 0.08% | 12.08% | ― |
* General Sector Average
IN:FDC
FDC Ltd.
343.70
-108.74
-24.03%
IN:BLISSGVS
Bliss Gvs Pharma Limited
559.10
400.06
251.54%
IN:INDOCO
Indoco Remedies Limited
242.30
-32.16
-11.72%
IN:ORCHPHARMA
Orchid Pharma Limited
929.20
182.85
24.50%
IN:STAR
Strides Pharma Science Ltd
982.45
140.24
16.65%
IN:UNICHEMLAB
Unichem Laboratories Limited
537.50
30.15
5.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.